Here's what to expect from the Australian-based global biotechnology company this year. The post Prediction: CSL shares could ...

CSL Behring’s largest-ever trial has ended in failure, as the Australian pharma revealed that its cholesterol efflux enhancer was unable to reduce the risk of heart attacks. The company had been ...

With plasma collection as its stock-in-trade, the struggles of CSL during the coronavirus lockdown were understandable. But a rebound—fueled by a surge in post-pandemic collections and an $11.7 ...

The FDA has approved the first hemophilia B gene therapy, a one-time treatment that addresses a root cause of this inherited disorder and potentially eliminates the need for regular infusions that ...

After shocking investors in 2025, CSL shares may be setting up for a comeback. Here’s why 2026 could look better. The post ...

CSL Ltd (ASX: CSL) shares were sold off in 2025. Let's find out why and see if this is a buying opportunity for ...

Steven Ewing spent his childhood reading car magazines, making his career as an automotive journalist an absolute dream job. After getting his foot in the door at Automobile while he was still a ...

CSL Limited, a biotechnology company that produce many of its biological products from plasma, is diversifying its portfolio and its drug pipeline through its largest ever acquisition: the purchase of ...

If you are wondering whether Carlisle Companies is priced attractively right now, the recent share performance gives you a useful starting point but not the full story. The stock closed at US$336.05 ...